Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in <i>TP53</i> -Mutant Cancers

16 Aug 2022

Abstract excerpt

DNA repair pathway inhibitors are a new class of anticancer drugs that are advancing in clinical trials. Peposertib is an inhibitor of DNA-dependent protein kinase (DNA-PK), which is a key driver of nonhomologous end-joining (NHEJ). To identify regulators of response to peposertib, we performed a genome-wide CRISPR knockout screen and found that loss of POLQ (polymerase theta, POLθ) and other genes in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35972384
DOI: 10.1158/0008-5472.can-22-1124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in <i>TP53</i> -Mutant CancersPMID 35972384Read ↗

Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiencySemantic proximity Read ↗

Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editingSemantic proximity Read ↗

Hyperactive end joining repair mediates resistance to DNA damaging therapy in p53-deficient cellsSemantic proximity Read ↗

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksSemantic proximity Read ↗

Anticipating on-target resistance to WRN inhibitors in microsatellite unstable cancersSemantic proximity Read ↗

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant CancersSemantic proximity Read ↗

TFU72 is a novel and potent DNA-PKcs inhibitor for enhancing homology-directed repair gene editingSemantic proximity Read ↗

Modulating mutational outcomes and improving precise gene editing at CRISPR-Cas9-induced breaks by chemical inhibition of end-joining pathways.Semantic proximity Read ↗

DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.Semantic proximity Read ↗

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksSemantic proximity Read ↗

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancersSemantic proximity Read ↗

Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.